

6th ESDO MASTERCLASS

Multidisciplinary Challenges in GI Cancers



November 18 - 19, 2022

Brussels, Belgium

Venue: KBR - Royal Library of Belgium, 1000 Brussels, Kunstberg 28 www.kbr.be

Registration is open > Join us

Internationally renowned experts with multidisciplinary views will discuss and integrate the latest data in gastrointestinal oncology, engaging in debates about novel challenges and anticipating new perspectives in the treatment and rapidly evolving therapeutic management of digestive cancers. The Masterclass is held in a small-size face-to-face format over 2 days with interactive discussions, pro/contra debates and case presentations, including a social evening programme. It is organised by the **European Society of Digestive Oncology** and the **Belgian Group of Digestive Oncology**.

The Organising Committee:

Prof. Eric Van Cutsem
ESDO President

Prof. Alain Hendlisz
BGDO President

Prof. Jean-Luc Van Laethem
Scientific Committee Chair

The Scientific Committee:

ESDO

Thomas Gruenberger, Austria
Tamara Matysiak-Budnik, France
Thomas Seufferlein, Germany
Eric Van Cutsem, Belgium
Jean-Luc Van Laethem, Belgium

BGDO

Ivan Borbath, Belgium
Saskia Carton, Belgium
Karen Geboes, Belgium
Alain Hendlisz, Belgium
Timon Vandamme, Belgium

ESDO Young Group

Alica Beutel, Germany
Ana-Maria Bucalau, Belgium
Pieter-Jan Cuyle, Belgium
Michela Guardascione, Italy

Organisation:

Liz Tanzer tel. +43 1405 1383 38
masterclass@esdo.eu
ESDO c/o WMA GmbH
1090 Vienna, Alser Strasse 4

Onsite Organisation & Registration:

Anne-Sophie Wirtz tel. + 32 476 312 411
management@bgdo.org
BGDO 1930 Zaventem
Leuvensesteenweg 643 b 8

Multidisciplinary challenges in GI cancers

Friday 18 November 2022

9:00 - 18:00

Part 1: Oncosurgical challenges for localised upper GI cancer

9h00 Welcome

Localised esophagogastric/GE junction cancers: more or less chemoRT?

9h10 Case: voting and discussion

9h20 Systemic therapy is the golden bullet to approach localised OG/GEJ tumours (including chemo +/- IO)

9h35 Chemoradiation should be the standard to approach localised OG/GEJ tumours and to go for watch-and-wait strategy in EG cancers?

9h50 Discussion

Localised pancreatic adenocarcinoma: more or less (neo)adjuvant therapy?

10h00 Case: voting and discussion

10h10 We should shift to neo-adjuvant therapy for all PDAC patients (including RT)

10h25 Upfront surgery followed by adjuvant treatment is still a valid option

10h40 Discussion

10h50 Coffee Break

Borderline resectable biliary tract cancer: more neoadjuvant therapy?

11h20 Case: voting and discussion

11h30 Neo-adjuvant therapy offers many opportunities for borderline resectable BTC (chemo? IO? SIRT?)

11h45 Borderline resectable BTC should be tackled primarily by surgical techniques

12h00 Discussion

BCLC stage B hepatocellular carcinoma: more or less locoregional therapy?

12h10 Case: voting and discussion

12h20 Locoregional therapy remains the standard for BCLC stage B.

12h35 Systemic therapy is now a good option in HCC BCLC stage B.

12h50 Discussion

13h00 Lunch Break

Multidisciplinary challenges in GI cancers

Part 2: Personalised approaches for pushing the boundaries in GI oncology

14h00 Welcome

CRC stage II(III): more ctDNA, less clinicopathological prognostication?

14h10 Case: voting and discussion

14h20 ctDNA is the most reliable biomarker to drive CRC stage II/III decision making

14h35 Clinicopathological factors including immune infiltrates should drive stage II/III decision making.

14h50 Discussion

Rectal cancer: more TNT, less surgery?

15h00 Case: voting and discussion

15h10 A radiation oncologist's view on organ sparing strategies in rectal cancer

15h25 An oncologist's view on organ sparing strategies in rectal cancer

15h40 Discussion

15h50 Coffee Break

Liver-limited CRC metastases: more or less perioperative chemotherapy?

16h20 Liver-limited mCRC case: voting and discussion

16h30 We should go for downstaging and resection/ablation therapy in all patients

16h45 We should only select good candidates for this strategy

17h00 Discussion

Oligometastatic non-CRC GI malignancies: more locoregional approaches or just systemic therapy?

17h10 Case: voting and discussion

17h20 We should implement more surgical/locoregional approaches in oligometastatic GI cancer

17h35 We should stick to systemic therapy for systemic diseases

17h50 Discussion

18h00 End of day 1

Multidisciplinary challenges in GI cancers

Saturday 19 November 2022 9:00 - 12:00

PART 3 Precision medicine ready for daily practice?

9h00 Welcome

Microsatellite instable GI cancers: less or even no surgery needed?

9h10 Case: voting and discussion

9h20 Do we need surgery in MSI-high colorectal cancer?

9h35 Do we need surgery in MSI-high non-colorectal cancer?

9h50 Discussion

Precision medicine in advanced GI cancer

10h00 Case: voting and discussion

10h10 When and how to implement precision medicine in advanced colorectal cancer?

10h25 When and how to implement precision medicine in advanced non-colorectal cancer?

10h40 Discussion

10h50 Coffee Break

Tumour response evaluation: more metabolic, less morphologic?

11h10 - pro metabolic
- pro morphologic

Molecular imaging in GI oncology:

11h45 Current indications and theranostic perspectives

12h30 End